BLUE - bluebird bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
119.84
+3.35 (+2.88%)
As of 12:05PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close116.49
Open115.44
Bid119.04 x 800
Ask119.47 x 900
Day's Range114.43 - 119.84
52 Week Range102.21 - 236.17
Volume194,208
Avg. Volume710,180
Market Cap6.555B
Beta (3Y Monthly)3.30
PE Ratio (TTM)N/A
EPS (TTM)-9.51
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est200.65
Trade prices are not sourced from all markets
  • Business Wire4 hours ago

    bluebird bio to Present at the Evercore ISI HealthCONx Conference

    bluebird bio, Inc. (BLUE) today announced that members of the management team will present at the Evercore ISI HealthCONx Conference, Wednesday, November 28, at 4:15 p.m. ET at the Boston Harbor Hotel, Boston. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors & Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conferences.

  • Waiting for bluebird bio to Sing at ASH
    Motley Fool6 days ago

    Waiting for bluebird bio to Sing at ASH

    The American Society of Hematology meeting will be a big event for the biotech.

  • Here's Why bluebird bio Fell 21.4% in October
    Motley Fool8 days ago

    Here's Why bluebird bio Fell 21.4% in October

    In September and October, investors thought Amgen set the bar in multiple myeloma too high, but in November bluebird bio teased promising data of its own.

  • 3 Cancer Stocks to Watch in December
    Motley Fool8 days ago

    3 Cancer Stocks to Watch in December

    Shares of these biotechs could surge following presentations at an important medical conference.

  • 3 Top Biotech Stocks to Buy in November
    Motley Fool8 days ago

    3 Top Biotech Stocks to Buy in November

    If you don't consider adding these biotech stocks to your portfolio this month, you could wind up missing out on an opportunity.

  • ACCESSWIRE9 days ago

    Today's Research Reports on Trending Tickers: bluebird bio and Geron

    NEW YORK, NY / ACCESSWIRE / November 6, 2018 / U.S. equities closed mostly higher on Monday as investors awaited details from the Fed's two-day policy meeting and midterm congressional elections. The Dow ...

  • bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat
    Zacks13 days ago

    bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat

    bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.

  • Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates
    Zacks14 days ago

    Bluebird Bio (BLUE) Reports Q3 Loss, Tops Revenue Estimates

    Bluebird (BLUE) delivered earnings and revenue surprises of 5.21% and 39.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Here's Why bluebird bio Jumped 13.5% Today
    Motley Fool14 days ago

    Here's Why bluebird bio Jumped 13.5% Today

    Early data from the American Society of Hematology meeting suggests the biotech's drug pipeline is as strong as ever.

  • Business Wire14 days ago

    bluebird bio Reports Third Quarter 2018 Financial Results and Highlights Operational Progress

    – Company plans to pursue accelerated development pathway for LentiGlobinTM in sickle cell disease –

  • Business Wire14 days ago

    bluebird bio to Present New Data from Early- and Late-Stage Pipeline of Investigational Gene and Cell Therapies at the American Society of Hematology Annual Meeting

    – Initial data from Phase 3 studies of LentiGlobin™ gene therapy in transfusion-dependent β-thalassemia for β0/β0 genotype and updated data in non-β0/β0 genotype –

  • ACCESSWIRE15 days ago

    Today's Research Reports on Trending Tickers: bluebird bio and Sarepta Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 31, 2018 / U.S. markets rebounded on Tuesday as trade tensions eased after President Trump hinted that the U.S. was prepared to negotiate a trade deal with China. During a Fox News interview with Laura Ingraham, President Trump said the U.S. “will make a great deal with China and it has to be great, because they’ve drained our country.” The Dow Jones Industrial Average gained 1.77 percent to close at 24,874.64, while the S&P 500 Index increased 1.57 percent to close at 2,682.63. The Nasdaq Composite Index jumped 1.58 percent to close at 7,161.65.

  • Analysts Expect Incyte to Report Revenue Growth in Third Quarter
    Market Realist20 days ago

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    As discussed earlier, analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018. The below graph compares the revenues of Incyte since the first quarter of 2017 and estimates for the third quarter of 2018. Incyte’s revenue stream includes product sales, royalty revenues, and other revenues from collaborations. Incyte acquired the commercial rights for Iclusig from Ariad Pharmaceuticals in 2016.

  • Here's Why I'm Not Selling My Celgene Shares
    Motley Fool20 days ago

    Here's Why I'm Not Selling My Celgene Shares

    The company could be about to get back on track following some high-profile stumbles.

  • Here's Why bluebird bio Dropped 13.3% in September
    Motley Foollast month

    Here's Why bluebird bio Dropped 13.3% in September

    The biopharma's multimonth stock slide continued, courtesy of promising preclinical results released by Amgen.

  • Business Wirelast month

    bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application for LentiGlobin™ Gene Therapy for the Treatment of Transfusion-Dependent β-Thalassemia

    LentiGlobin was previously granted an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP) of the EMA in July 2018, potentially reducing the EMA’s active review time of the MAA from 210 days to 150 days. “People living with transfusion-dependent β-thalassemia require frequent blood transfusions that are life-saving but may lead to complications, including organ failure due to iron overload,” said David Davidson, M.D., chief medical officer, bluebird bio.

  • Business Wirelast month

    bluebird bio to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

    bluebird bio, Inc. (BLUE) today announced that members of the management team will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology, Wednesday, October 3, at 3:30 p.m. ET at the Lotte New York Palace, New York City. To access the live webcast of bluebird bio’s presentation, please visit the “Events & Presentations” page within the Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com. A replay of the webcast will be available on the bluebird bio website for 90 days following the conferences.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: bluebird bio and Regeneron Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 28, 2018 / U.S. markets finished higher on Thursday as the jobless claims increase was smaller than expected and second quarter GDP rose 3.1%, marking the best growth ...

  • A Look at Sage Therapeutics’ NMDA Receptor Portfolio
    Market Realist2 months ago

    A Look at Sage Therapeutics’ NMDA Receptor Portfolio

    As discussed earlier, Sage Therapeutics (SAGE) is focused on the development of products for the treatment of life-threatening central nervous system (or CNS) disorders. The products under development include SAGE-718 and SAGE-904.

  • Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory
    Motley Fool2 months ago

    Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory

    Cellular cancer therapies are a tough sell that could get a lot tougher.

  • Analyzing Regenxbio’s Valuation Metrics
    Market Realist2 months ago

    Analyzing Regenxbio’s Valuation Metrics

    Regenxbio (RGNX) generated revenues, chiefly from licensing, of $40.03 million in the second quarter compared to $6.56 million in Q2 2017. For fiscal 2018, Regenxbio is expected to generate revenues of $194.55 million compared to $10.39 million in fiscal 2017. The increase in revenues helped Regenxbio generate a net income of $10.59 million in the second quarter compared to a net loss of $14.47 million in the second quarter of 2017.

  • 56% of Analysts Recommend a ‘Buy’ for Editas Medicine
    Market Realist2 months ago

    56% of Analysts Recommend a ‘Buy’ for Editas Medicine

    In August, the National Institutes of Health’s (or NIH) recombinant DNA advisory committee completed the NIH protocol for Editas Medicine’s (EDIT) EDIT-101. EDIT-101 is an investigational CRISPR genome editing therapy for the treatment of individuals with LCA10 (Leber Congenital Amaurosis type 10). Editas Medicine plans to submit an IND (Investigational New Drug) application to the FDA in October.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: bluebird bio and PTC Therapeutics

    NEW YORK, NY / ACCESSWIRE / September 7, 2018 / U.S. benchmarks closed mostly lower on Thursday, with the Dow Jones remaining in the green, as internet and tech shares slumped. The Dow Jones Industrial ...

  • Estimates and Recommendations for Bluebird Bio on September 6
    Market Realist2 months ago

    Estimates and Recommendations for Bluebird Bio on September 6

    Wall Street analysts estimate that Bluebird Bio (BLUE) will report a 14.6% growth in revenues to ~$40.6 million in 2018 compared to $35.4 million in 2017. Its EPS is expected to be -$10.83 in 2018. Analysts estimate net adjusted loss of $556.6 million in 2018.

  • Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy
    Market Realist2 months ago

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating the investigational Lenti-D gene therapy for the treatment of cerebral adrenoleukodystrophy (or CALD) in boys aged 17 years or less. The Phase 2/3 Starbeam study met its enrollment goal with the data reported by Bluebird Bio as of April 25. Thirty-one patients were studied, and 29 of them received Lenti-D gene therapy.